[Current status and outcomes analysis of radiosurgery for spinal tumours]
Chung CK, Kim J, Park E, Lee NR, Lee Y, Shin E, Kim SH, Sohn MJ, Chang UK, Sohn S
Record ID 32014001094
Authors' recomendations: National health insurance claim data and retrospective patient cohort data were utilized to provide the prevalence and incidence of Korean spinal tumor patients, medical use, and therapeutic condition of the treatments for spine tumor patients. In Korea, the number of spinal tumor patients and the medical use are increasing every year. Considering that the survival rate and the survival period of the cancer patients are extended from the recent development of health technology, it is expected that metastatic spinal tumor patients will increase more. Therefore, it is considered that development of medical health policy related to reasonable spinal tumor therapy in which all relevant therapeutic fields, such as neurosurgery and radiation oncology, are all considered will be required. The therapeutic performance of the radiosurgery and radiation therapy in metastatic spinal tumor patients was not clearly identified through retrospective patient cohort. Furthermore, and for radiosurgery, the number of fractionated therapy was short, but the patient's physical pressure was high on therapy, and, for single of two metastases, therapeutic performance could be good. For metastatic spinal tumor patients, considering that the median survival period is 6-12 months, selecting the reasonable radiation therapy by taking into account the strong and weak point between the therapies will be necessary. Currently, clinical departments mostly participate in radiosurgery in the settings of neurosurgery and radiation oncology. Selecting and applying treatment through collaboration between the two clinical departments that are best for the patient is required, and performance of mutual collaborative clinical trials to for determine the best clinical basis is necessary. Especially, performance of multi-center, prospective randomized controlled clinical trials to provide the therapeutic performance and indications will be necessary.
Project Status: Completed
Year Published: 2014
URL for published report: http://www.neca.re.kr/center/researcher/report_view.jsp?boardNo=GA&seq=110&q=626f6172644e6f3d4741
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
- Spinal Neoplasms
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.